Meet Clay Siegall, a Scientist, and CEO of Seattle Genetics

Clay Siegall is an entrepreneur, a business executive as well as a scientist. He co-founded of Seattle Genetics in 1998, a biotech firm that focuses on the development of therapeutic drugs. Clay Siegall aims at transferring cancer treatments from systemic chemotherapies to tolerable more efficacious targeted medicines. Clay Siegall believes for one to succeed one has to be passionate and work hard.

Seattle Genetics researches and develops the antibody drugs, which are approved by FDA. Also, it has formed a strategic partnership with large pharmaceutical companies like Genentech, Bayer, and Pfizer.

Clay Siegall became interested in cancer diagnosis while studying zoology at Maryland University. A family member diagnosed with cancer had brutal chemotherapy treatment that resulted to anemia. He started Seattle Genetics to have autonomy on his projects. Furthermore, he needed to earn money especially from the development and marketing of the drug approved by FDA.

The running of Seattle Genetics was not that smooth as they experienced financial threat two years after inception. Early 2000, the firm brought in talented sales staff with a background in the biotech. The move did bear fruits, and a decade after the IPO the company did break even. The company management and legal team invest a lot of time in meetings and negotiating as a market strategy.

About Clay Siegall

Clay Siegall is the president and the CEO of Seattle Genetics. Siegall has steered the company to be a leader in research and development of drugs across the globe. An author of 70 publications and holder of 15 patents, Siegall is an alumnus of Maryland University where he graduated with B.S in Zoology. Also, he has a doctorate in genetics from George Washington University.

Dr. Siegall has had an illustrious career in the health industry before joining Seattle Genetics. Between 1991to 1997, he worked with the Bristol-Myers Squibb Pharmaceutical Research Institute. Also, from 1988 to 1991 he served with the National Cancer Centre as well as National Institute of Health. Dr. Siegall is a board member of Washington Roundtable, Ultragenyx Pharmaceutical, and Alder BioPharmaceuticals. He has received various awards like the 2012 Ernst & Young Entrepreneur of the year for Pacific Northwest.

Leave a Reply